Monopar Therapeutics

MNPR

Market cap $304M

Overview Fund Activity

49.22 USD

+1.55

3.25%

At close Updated Sep 12, 4:00 PM EDT

1 day

3.25%

5 days

10.66%

1 month

37.1%

3 months

45.54%

6 months

59.29%

Year to date

121.51%

1 year

1,146.08%

5 years

80.29%

10 years

-62.85%

About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Employees: 16

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

275% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 4

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

23% more funds holding

Funds holding: 35 [Q1] → 43 (+8) [Q2]

4.63% more ownership

Funds ownership: 47.31% [Q1] → 51.94% (+4.63%) [Q2]

4% more capital invested

Capital invested by funds: $109M [Q1] → $113M (+$3.93M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$60

22% upside

Avg. target

$75

52% upside

High target

$87

77% upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

BTIG Jeet Mukherjee	$87	Buy Initiated	9 Sep 2025
Raymond James Chris Raymond	$80	Strong Buy Initiated	3 Sep 2025
Oppenheimer Andreas Argyrides	$77	Outperform Initiated	3 Sep 2025
Cantor Fitzgerald Kristen Kluska	$74	Overweight Reiterated	27 Aug 2025
HC Wainwright & Co. Andres Y. Maldonado	$70	Buy Assumed	26 Aug 2025
Chardan Capital Keay Nakae	$60	Buy Maintained	13 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about MNPR published over the past 30 days

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan. Monopar's poster presentation is available at the following link: https://www.monopartx.com/ALXN1840-ANA-2025-Poster-14-Sep-2025. The oral presentation will be made available online at www.monopartx.com concurrently with Dr. Lorincz's presentation on September 15, 2025.

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Monopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown superior efficacy over standard of care in Phase 3, with potential peak sales of $500M and an NDA filing targeted for early 2026. The radiopharmaceuticals pipeline is advancing in Phase 1, with strong M&A interest in the sector providing additional upside and derisking the investment case.

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association (ANA) Annual Meeting, to be held September 13-16, 2025, in Baltimore, Maryland.

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments.

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Zacks Investment Research

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center (“EDNOC”), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded Access Program (“EAP”) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration (“FDA”).

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025.

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, a leading global conference in liver disease.

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025.

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

See News Rankings

Charts implemented using Lightweight Charts™